Impact of setanaxib on quality of life outcomes in primary biliary cholangitis in a phase 2 randomized controlled trial

Background:. There is a real unmet need for primary biliary cholangitis (PBC) treatments that can improve quality of life impacting symptoms. In this post hoc analysis, we evaluated potential effects of the NADP oxidase 1/4 inhibitor, setanaxib, on patient-reported quality of life from a phase 2 tri...

Full description

Bibliographic Details

Published in:	Hepatology Communications
Main Authors:	David Jones, Marco Carbone, Pietro Invernizzi, Nicola Little, Frederik Nevens, Mark G. Swain, Philippe Wiesel, Cynthia Levy
Format:	Article
Language:	English
Published:	Wolters Kluwer Health/LWW 2023-03-01
Online Access:	http://journals.lww.com/10.1097/HC9.0000000000000057